| Revenue growth | Q2 +23% YoY; H1 +17% YoY |
|---|---|
| Margins | Q2 EBITDA 28% vs 29% YoY; PAT 15% vs 16% |
| Demand visibility | More large pharma integrated-model talks underway |
| Management confidence | Mgmt expects stronger second half |
Growth
Q2 revenue +23% YoY to ₹659 Cr; Q2 PAT +17% to ₹98 Cr. H1 PAT +19% to ₹172 Cr.
Outlook
No numeric guidance; management expects stronger H2. Overall capex ₹1,100–1,300 Cr. New integrated collaboration fully functional by Q3.
Risks
Q2 EBITDA margin down ~1ppt YoY (29% to 28%). Q2 D&A up 20% YoY. Heavy capex load pressures depreciation.
Last quarter's promises, checked
Partly delivered
- Mid-term rev growth 15–20% → H1 +17% YoY (= PARTIAL: in band, multi-year test still open)
- EBITDA margin 28–30% → Q2 28%, down from 29% YoY (= PARTIAL: at floor of band)
- Two large pharma to integrated models in 2026 → one converted (= PARTIAL: half done at mid-year)
Investor Presentation filed with NSE, NSE: SAILIFE. Summary written with AI assistance from the document.
Sai Life Science Ltd: key numbers
- Share price
- ₹1,594.50
- Market cap
- ₹33,879 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 93.7×Sector 42.0×
- Promoter holding
- 34.50%-0.03% QoQ
- FII holding
- 19.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Life Science Ltd
All →Sai Life Science Results Update
Sai Life Sciences posted Q2 FY27 revenue growth of 23% YoY, with H1 PAT up 19% to ₹172 Cr. The company incurred ₹621 Cr capex in H1.
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 108,005 ESOP equity shares, taking paid-up capital to Rs.21.26 Crore. No stated consideration means no event value.
Sai Life Science Management Change
Sai Life Sciences appointed three senior management personnel effective 5 November 2026. The appointees include Sidhartha Das as Senior Vice President and Head of Human Resources.
Sai Life Science Q2 FY27 Results: Net Profit ₹98.3 Cr, Up 17.3% YoY
Sai Life Science Ltd reported revenue from operations of ₹658.6 Cr (+22.5% YoY) and net profit of ₹98.3 Cr (+17.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹98.3 Cr · +17.3% YoY
Sai Life Science Employee Stock Options
Sai Life Sciences allotted 54,500 equity shares upon the exercise of employee stock options under its ESOP 2008 plan, increasing the total paid-up share capital.
Sai Life Science Other Announcement
Routine quarterly shareholding pattern filing for the quarter ended September 30, 2026, as mandated by SEBI LODR regulations.